Featured

Fresh off fundraising trail, Georgian Partners leads TraceLink’s $93 mln round

Georgian Partners, which only weeks ago closed its fourth fund, is backing a software provider that aims to rid the global marketplace of counterfeit drugs. TraceLink, a Boston pharmaceuticals-tracking platform, said today that it raised a US$93 million financing led by the Canadian growth equity firm. Georgian Partner Tyson Baber joined the board. Founded in 2009, TraceLink provides a network for drugmakers and other stakeholders in the global life-sciences supply chain to connect and share information in real time. Along with leading its round, Georgian will support the company's artificial intelligence and machine learning strategy.

Defy defies the odds in funding Series A companies

Five Questions with Susan Choe of Katalyst Ventures

SVB’s Bob Blee: ideal IPO environment, more mid-market M&A

July Dashboard: Fundraising keeps climbing as exits and deals slow somewhat

22x Fund offers investors refunds months after launching venture-competitor token sale

SHS Fund V giving digital health a financial shot in the arm

July's Top 10: Capital continues to concentrate into mega venture deals

Benhamou Global Ventures raises $40 mln for first opportunity fund

Georgian Partners closes fourth tech fund at $550 mln, continues hiring spree